VRDN FY 2016 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+31.5% YoY

Gross Profit

$789,00023.6% margin

Operating Income

-$13M-374.8% margin

Net Income

-$13M-379.8% margin

EPS (Diluted)

$-17.57

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$4M

Total Liabilities

$5M

Stockholders' Equity

-$326,000

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	+31.5%
Gross Profit	$789,000	$66,000	+1095.5%
Operating Income	-$13M	-$11M	-11.8%
Net Income	-$13M	-$11M	-11.9%